Standard
Update June 2022 : management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. / Roche, Nicolas; Crichton, Megan L.; Goeminne, Pieter C.; Cao, Bin; Humbert, Marc; Shteinberg, Michal; Antoniou, Katerina M.; Ulrik, Charlotte Suppli; Parks, Helen; Wang, Chen; Vandendriessche, Thomas; Qu, Jieming; Stolz, Daiana; Brightling, Christopher; Welte, Tobias; Aliberti, Stefano; Simonds, Anita K.; Tonia, Thomy; Chalmers, James D.
In:
European Respiratory Journal, Vol. 60, No. 2, 2200803, 2022.
Research output: Contribution to journal › Review › Research › peer-review
Harvard
Roche, N, Crichton, ML, Goeminne, PC, Cao, B, Humbert, M, Shteinberg, M, Antoniou, KM
, Ulrik, CS, Parks, H, Wang, C, Vandendriessche, T, Qu, J, Stolz, D, Brightling, C, Welte, T, Aliberti, S, Simonds, AK, Tonia, T & Chalmers, JD 2022, '
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline',
European Respiratory Journal, vol. 60, no. 2, 2200803.
https://doi.org/10.1183/13993003.00803-2022APA
Roche, N., Crichton, M. L., Goeminne, P. C., Cao, B., Humbert, M., Shteinberg, M., Antoniou, K. M.
, Ulrik, C. S., Parks, H., Wang, C., Vandendriessche, T., Qu, J., Stolz, D., Brightling, C., Welte, T., Aliberti, S., Simonds, A. K., Tonia, T., & Chalmers, J. D. (2022).
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.
European Respiratory Journal,
60(2), [2200803].
https://doi.org/10.1183/13993003.00803-2022Vancouver
Roche N, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M et al.
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.
European Respiratory Journal. 2022;60(2). 2200803.
https://doi.org/10.1183/13993003.00803-2022Author
Roche, Nicolas ; Crichton, Megan L. ; Goeminne, Pieter C. ; Cao, Bin ; Humbert, Marc ; Shteinberg, Michal ; Antoniou, Katerina M. ; Ulrik, Charlotte Suppli ; Parks, Helen ; Wang, Chen ; Vandendriessche, Thomas ; Qu, Jieming ; Stolz, Daiana ; Brightling, Christopher ; Welte, Tobias ; Aliberti, Stefano ; Simonds, Anita K. ; Tonia, Thomy ; Chalmers, James D. / Update June 2022 : management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. In: European Respiratory Journal. 2022 ; Vol. 60, No. 2.
Bibtex
@article{2f3e88a0e8a24d44a4c486c336eac277,
title = "Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline",
author = "Nicolas Roche and Crichton, {Megan L.} and Goeminne, {Pieter C.} and Bin Cao and Marc Humbert and Michal Shteinberg and Antoniou, {Katerina M.} and Ulrik, {Charlotte Suppli} and Helen Parks and Chen Wang and Thomas Vandendriessche and Jieming Qu and Daiana Stolz and Christopher Brightling and Tobias Welte and Stefano Aliberti and Simonds, {Anita K.} and Thomy Tonia and Chalmers, {James D.}",
note = "Funding Information: Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from GSK, AstraZeneca, Chiesi, Sanofi and Zambon, outside the submitted work. M.L. Crichton reports personal fees from AstraZeneca, outside the submitted work. P.C. Goeminne reports personal fees for lectures from GSK and AstraZeneca, grants, personal fees for advisory board work and non-financial support for meeting attendance from Chiesi, outside the submitted work. B. Cao reports personal fees from F. Hoffmann-La Roche Ltd as a member of steering committee in transmission study of baloxavir, and grants from Peking Union Medical College Foundation, outside the submitted work. M. Humbert reports grants, personal fees and non-financial support from GlaxoSmithKline, personal fees from AstraZeneca, Novartis, Roche, Sanofi, Teva and Merck, grants and personal fees from Acceleron, Actelion and Bayer, outside the submitted work. M. Shteinberg reports grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, personal fees from Boehringer Ingelheim, AstraZeneca, Kamada, Vertex pharmaceuticals, Teva and Zambon, non-financial support from Actelion and Rafa, outside the submitted work. C.S. Ulrik reports personal fees from AstraZeneca, GSK, Chiesi, Orion Pharma and TEVA, grants and personal fees from Boehringer Ingelheim, Sanofi Genzyme and Novartis, grants from Mundipharma, outside the submitted work. D. Stolz reports grants from AstraZeneca AG, Curetis AG and Boston Scientific, lecture fees from AstraZeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer, Schwabe Pharma AG and Vifor AG, outside the submitted work. T. Welte reports grants from German Ministry of Health, German Ministry of Research and Education, DFG, WHO and EU, during the conduct of the study; personal fees for lectures/advisory board work from Roche, AstraZeneca, Boehringer, GSK and Novartis, outside the submitted work. S. Aliberti reports personal fees for advisory board work and research support from Bayer Healthcare, personal fees for lectures from Grifols and Menarini, personal fees for advisory board work from AstraZeneca and ZetaCube Srl, personal fees for advisory board work and lectures from Zambon and GlaxoSmithKline, grants and personal fees advisory board work and lectures from Chiesi and INSMED, grants from Fisher & Paykel, outside the submitted work. T. Tonia acts as ERS Methodologist. J.D. Chalmers reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Insmed, personal fees from Chiesi, Novartis and Zambon, grants from Gilead Sciences, outside the submitted work. The remaining authors disclose no potential conflicts of interest. Funding Information: Funded by the European Respiratory Society through the COVID-19 Living Guidelines Task Force (2020-14). Funding information for this article has been deposited with the Crossref Funder Registry.",
year = "2022",
doi = "10.1183/13993003.00803-2022",
language = "English",
volume = "60",
journal = "The European respiratory journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",
}
RIS
TY - JOUR
T1 - Update June 2022
T2 - management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
AU - Roche, Nicolas
AU - Crichton, Megan L.
AU - Goeminne, Pieter C.
AU - Cao, Bin
AU - Humbert, Marc
AU - Shteinberg, Michal
AU - Antoniou, Katerina M.
AU - Ulrik, Charlotte Suppli
AU - Parks, Helen
AU - Wang, Chen
AU - Vandendriessche, Thomas
AU - Qu, Jieming
AU - Stolz, Daiana
AU - Brightling, Christopher
AU - Welte, Tobias
AU - Aliberti, Stefano
AU - Simonds, Anita K.
AU - Tonia, Thomy
AU - Chalmers, James D.
N1 - Funding Information:
Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from GSK, AstraZeneca, Chiesi, Sanofi and Zambon, outside the submitted work. M.L. Crichton reports personal fees from AstraZeneca, outside the submitted work. P.C. Goeminne reports personal fees for lectures from GSK and AstraZeneca, grants, personal fees for advisory board work and non-financial support for meeting attendance from Chiesi, outside the submitted work. B. Cao reports personal fees from F. Hoffmann-La Roche Ltd as a member of steering committee in transmission study of baloxavir, and grants from Peking Union Medical College Foundation, outside the submitted work. M. Humbert reports grants, personal fees and non-financial support from GlaxoSmithKline, personal fees from AstraZeneca, Novartis, Roche, Sanofi, Teva and Merck, grants and personal fees from Acceleron, Actelion and Bayer, outside the submitted work. M. Shteinberg reports grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, personal fees from Boehringer Ingelheim, AstraZeneca, Kamada, Vertex pharmaceuticals, Teva and Zambon, non-financial support from Actelion and Rafa, outside the submitted work. C.S. Ulrik reports personal fees from AstraZeneca, GSK, Chiesi, Orion Pharma and TEVA, grants and personal fees from Boehringer Ingelheim, Sanofi Genzyme and Novartis, grants from Mundipharma, outside the submitted work. D. Stolz reports grants from AstraZeneca AG, Curetis AG and Boston Scientific, lecture fees from AstraZeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer, Schwabe Pharma AG and Vifor AG, outside the submitted work. T. Welte reports grants from German Ministry of Health, German Ministry of Research and Education, DFG, WHO and EU, during the conduct of the study; personal fees for lectures/advisory board work from Roche, AstraZeneca, Boehringer, GSK and Novartis, outside the submitted work. S. Aliberti reports personal fees for advisory board work and research support from Bayer Healthcare, personal fees for lectures from Grifols and Menarini, personal fees for advisory board work from AstraZeneca and ZetaCube Srl, personal fees for advisory board work and lectures from Zambon and GlaxoSmithKline, grants and personal fees advisory board work and lectures from Chiesi and INSMED, grants from Fisher & Paykel, outside the submitted work. T. Tonia acts as ERS Methodologist. J.D. Chalmers reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Insmed, personal fees from Chiesi, Novartis and Zambon, grants from Gilead Sciences, outside the submitted work. The remaining authors disclose no potential conflicts of interest.
Funding Information:
Funded by the European Respiratory Society through the COVID-19 Living Guidelines Task Force (2020-14). Funding information for this article has been deposited with the Crossref Funder Registry.
PY - 2022
Y1 - 2022
U2 - 10.1183/13993003.00803-2022
DO - 10.1183/13993003.00803-2022
M3 - Review
C2 - 35710264
AN - SCOPUS:85136339483
VL - 60
JO - The European respiratory journal
JF - The European respiratory journal
SN - 0903-1936
IS - 2
M1 - 2200803
ER -
